51
Peter E Cross, Alexander R MacKenzie: Muscarinic receptor antagonists. Pfizer, Peter C Richardson, Paul H Ginsburg, Garth Butterfield, August 23, 1994: US05340831 (27 worldwide citation)

Muscarinic receptor antagonists of formula (I), and their pharmaceutically acceptable salts, wherein Y is --CH.sub.2 --, --(CH.sub.2).sub.2 --, --CH.sub.2 O--, --(CH.sub.2).sub.2 O-- or --CH.sub.2 S--; R is --CH or --CONH.sub.2 ; and R.sup.1 is a group of formula (a), where R.sup.2 and R.sup.3 are e ...


52
Nicholas D Cosford, Jean Michel Vernier: Substituted pyridines useful as modulators of acetylcholine receptors. Sibia Neurosciences, Stephen E Reiter, Pretty Schroeder Brueggemann & Clark, December 17, 1996: US05585388 (26 worldwide citation)

In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antag ...


53
Pascal Jean Claude, Lee Chi Ho, Alps Brian J, Pinhas Henri, Whiting Roger L, Beranger Serge: Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives.. Syntex Pharma, November 2, 1988: EP0289227-A1 (26 worldwide citation)

Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: wherein: R is aryl; R is aryl, C1-4 alkyl, or hydrogen; R is C1-4 alkyl, hydroxy, or hydrogen; R is aryl; R is aryl; m is two or three; n is zero, one or two, provided that when R is hydroxy, n is one or two; and q is ze ...


54
Allen William Dennis, Linggod Margaret Anneli, Porter Philip: Probiotic.. Quest Int, October 14, 1992: EP0508701-A2 (26 worldwide citation)

A novel strain of Enterococcus faecium, deposited as NCIMB 40371, has valuable probiotic properties and is particularly effective in alleviating symptoms of irritable bowel syndrome in human patients. The novel strain can be used in the manufacture of human foodstuffs.


55
Janssens Frans Eduard, Sommen François Maria, de, Boeck Benoît Christian Albert Ghislain, Leenaerts Joseph Elisabeth: Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists. Janssen Pharmaceutica, Janssens Frans Eduard, Sommen François Maria, de, Boeck Benoît Christian Albert Ghislain, Leenaerts Joseph Elisabeth, JANSSEN PHARMACEUTICA, July 8, 2004: WO/2004/056800 (26 worldwide citation)

The invention concerns substituted 1-piperidin-4-yl-4-azefdin-3-yl-piperazine having neurokinin antagonistic activity, in particular NK1 and NK1/NK3- antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of schizophrenia, ...


56
Allen Wayne Mangel, Allison Ruth Northcutt: Medicaments for the treatment of non-constipated female irritable bowel syndrome. Glaxo Wellcome, Lorie Ann Morgan, September 4, 2001: US06284770 (25 worldwide citation)

This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients.


57
Kato Tomoki, Kawamura Kiyoshi, Morita Mikio, Uchida Chikara: Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity. Pfizer Japan, Kato Tomoki, Kawamura Kiyoshi, Morita Mikio, Uchida Chikara, Pfizer, FULLER Grover F Jr, June 2, 2005: WO/2005/049608 (25 worldwide citation)

This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the ...


58
Uchida Chikara, Kawamura Kiyoshi, Kato Tomoki: 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity. Pfizer Japan, Uchida Chikara, Kawamura Kiyoshi, Kato Tomoki, Pfizer, FULLER Grover F Jr, August 11, 2005: WO/2005/073222 (25 worldwide citation)

This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the ...


59
Daniel P Becker, Daniel L Flynn, Alan E Moorman, Roger Nosal, Clara I Villamil: Meso-azacyclic aromatic acid amides and esters as novel serotonergic agents. G D Searle & Co, Cynthia S Kovacevic, Roger A Williams, March 18, 1997: US05612366 (24 worldwide citation)

The meso-azacyclic aromatic acid amides and esters of the present invention are useful in the treatment of the central nervous system and gastrointestinal motility disorders such as gastroesophageal reflux, non-ulcer dyspepsia, delayed gastric emptying, ileus, irritable bowel syndrome, and the like. ...


60
Daniel P Becker, Daniel L Flynn, Alan E Moormann, Roger Nosal, Clara I Villamil: Imidazopyridines as serotonergic 5-HT.sub.3 antagonists. G D Searle & Co, Cynthia S Kovacevic, Roger A Williams, July 18, 1995: US05434161 (24 worldwide citation)

The imidazopyridines compounds of the present invention are serotonergic 5-HT.sub.3 antagonists. As such they are useful for the treatment of humans and animals wherein antagonism of 5-HT.sub.3 receptors is beneficial. Therapy is indicated for, but not limited to, the treatment of anxiety, psychoses ...



Click the thumbnails below to visualize the patent trend.